Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.